ReviewCell communication and signaling : CCS2026
Apoptotic vesicles in cancer: research progress in physiology and therapy.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Apoptotic cells release a highly heterogeneous population of extracellular vesicles, which can be categorized into apoptotic bodies, apoptotic microvesicles, and apoptotic exosomes. These apoptotic vesicles (apoVs) not only inherit materials from their parental cells but also encapsulate apoptosis-related factors, thereby playing multifaceted roles in signal transduction, homeostatic regulation, and the tumor microenvironment. This review highlights recent advances in the cell biology of apoptotic extracellular vesicles, with a focus on the unique characteristics of tumor-derived ApoVs and their mechanisms of interaction in immune evasion, angiogenesis, and the modulation of the tumor microenvironment. Additionally, the potential of ApoEVs as biomarkers for tumor diagnostics is explored. In the realm of tumor therapy, engineered and modified ApoEVs have emerged as promising drug delivery vehicles and vaccine carriers, enabling targeted delivery of therapeutic agents and showing significant potential in antitumor immunization strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.